View in EDS

Cost-Effectiveness Analysis of Pertuzumab Plus Trastuzumab and Docetaxel Compared With Trastuzumab and Docetaxel in the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in Colombia.

Saved in:
Bibliographic Details
Title: Cost-Effectiveness Analysis of Pertuzumab Plus Trastuzumab and Docetaxel Compared With Trastuzumab and Docetaxel in the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in Colombia.
Authors: Guevara-Cuellar CA; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. Electronic address: cguevara@icesi.edu.co., Parody-Rúa E; Weber, Pharmacoeconomics and Market Access Department, Madrid, España., Rengifo-Mosquera MP; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia., Del Mar Conde-Crespo M; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia., Nuñez-Castro JM; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.
Source: Value in health regional issues [Value Health Reg Issues] 2022 Nov; Vol. 32, pp. 109-118. Date of Electronic Publication: 2022 Sep 29.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101592642 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2212-1102 (Electronic) Linking ISSN: 22121099 NLM ISO Abbreviation: Value Health Reg Issues Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36183606
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cost-Effectiveness Analysis of Pertuzumab Plus Trastuzumab and Docetaxel Compared With Trastuzumab and Docetaxel in the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in Colombia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Guevara-Cuellar+CA%22">Guevara-Cuellar CA</searchLink>; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. Electronic address: cguevara@icesi.edu.co.<br /><searchLink fieldCode="AU" term="%22Parody-Rúa+E%22">Parody-Rúa E</searchLink>; Weber, Pharmacoeconomics and Market Access Department, Madrid, España.<br /><searchLink fieldCode="AU" term="%22Rengifo-Mosquera+MP%22">Rengifo-Mosquera MP</searchLink>; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.<br /><searchLink fieldCode="AU" term="%22Del+Mar+Conde-Crespo+M%22">Del Mar Conde-Crespo M</searchLink>; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.<br /><searchLink fieldCode="AU" term="%22Nuñez-Castro+JM%22">Nuñez-Castro JM</searchLink>; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101592642%22">Value in health regional issues</searchLink> [Value Health Reg Issues] 2022 Nov; Vol. 32, pp. 109-118. <i>Date of Electronic Publication: </i>2022 Sep 29.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101592642 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2212-1102 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2222121099%22">22121099 </searchLink><i>NLM ISO Abbreviation: </i>Value Health Reg Issues <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36183606
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.vhri.2022.08.002
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 109
    Titles:
      – TitleFull: Cost-Effectiveness Analysis of Pertuzumab Plus Trastuzumab and Docetaxel Compared With Trastuzumab and Docetaxel in the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in Colombia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Guevara-Cuellar CA
      – PersonEntity:
          Name:
            NameFull: Parody-Rúa E
      – PersonEntity:
          Name:
            NameFull: Rengifo-Mosquera MP
      – PersonEntity:
          Name:
            NameFull: Del Mar Conde-Crespo M
      – PersonEntity:
          Name:
            NameFull: Nuñez-Castro JM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2022 Nov
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2212-1102
          Numbering:
            – Type: volume
              Value: 32
          Titles:
            – TitleFull: Value in health regional issues
              Type: main
ResultId 1